Jaideep Shenoi

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Steven I. Park, Jaideep Shenoi, John M. Pagel et al. · Blood · 2010 · 73 citations · Full text

Medicine, Immunology, Oncology +15

Detection of Catalase as a major protein target of the lipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLE

Anil D’Souza, Biji T. Kurien, Rosalie Rodgers et al. · BMC Medical Genetics · 2008 · 64 citations · Full text

Life Sciences, Biochemistry, Genetics +17

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

John M. Pagel, Aimee L. Kenoyer, Tom Bäck et al. · Blood · 2011 · 57 citations · Full text

Medicine, Hematology, Oncology +10

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Franklin C. Lee, William Proctor Harris, Heather H. Cheng et al. · Advances in Urology · 2013 · 42 citations · Full text

Medicine, Oncology, Urology +14

Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma

Steven Park, Jaideep Shenoi, Shani M. Frayo et al. · Clinical Cancer Research · 2011 · 30 citations · Full text

Pharmacy, Biotechnology, Oncology +17